Helix Biomedix Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2012. For the quarter, the company reported total revenue of $680,422 against $357,628 for the same period a year ago. Loss from operations was $546,193 against $726,645 for the same period a year ago. Net loss and comprehensive loss was $581,838 against $709,734 for the same period a year ago. Basic and diluted net loss per share were $0.01 against $0.01 for the same period a year ago. The year-over-year increase in revenue reflected a 120% increase in consumer product sales to NuGlow Cosmaceuticals, LLC, an affiliated company, an 87% increase in peptide and consumer product sales to non-affiliates and an 84% increase in licensing revenue. The decrease in net loss for 2012 compared to the prior year reflects revenue growth combined with continued operating expense controls as Helix BioMedix product volumes and license utilization have increased.